A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.

MLA

Ehlen, T. G., et al. “A Pilot Phase 2 Study of Oregovomab Murine Monoclonal Antibody to CA125 as an Immunotherapeutic Agent for Recurrent Ovarian Cancer.” International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, vol. 15, no. 6, Nov. 2005, pp. 1023–34. EBSCOhost, https://doi.org/10.1111/j.1525-1438.2005.00483.x.

APA

Ehlen, T. G., Hoskins, P. J., Miller, D., Whiteside, T. L., Nicodemus, C. F., Schultes, B. C., & Swenerton, K. D. (2005). A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 15(6), 1023–1034. https://doi.org/10.1111/j.1525-1438.2005.00483.x

Chicago

Ehlen, T G, P J Hoskins, D Miller, T L Whiteside, C F Nicodemus, B C Schultes, and K D Swenerton. 2005. “A Pilot Phase 2 Study of Oregovomab Murine Monoclonal Antibody to CA125 as an Immunotherapeutic Agent for Recurrent Ovarian Cancer.” International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 15 (6): 1023–34. doi:10.1111/j.1525-1438.2005.00483.x.